Introduction: transdermal drug delivery
=======================================

Patient adherence is a key issue that must be addressed to ensure the efficacy of hormonal contraception. Combined hormonal contraceptives are effective forms of reversible contraception, whose benefits have been established by a wealth of studies ([@b12-ppa-2-357]; [@b36-ppa-2-357]). Provided that they are taken regularly and correctly on a once-daily regimen, combined hormonal contraceptives are more than 99% effective and almost 100% reliable, the first-year pregnancy rate being less than 0.5% among perfectly conscientious users ([@b40-ppa-2-357]). However, from 19% to 47% of oral contraceptive users miss one or more pills per cycle ([@b37-ppa-2-357]) and this gap translates into thousands of unintended pregnancies annually ([@b2-ppa-2-357]). A more convenient method of administration has thus been sought, to reduce the risk of "missing pills".

Transdermal systems represent a milestone innovation in drug delivery, offering a number of advantages over the oral route ([@b42-ppa-2-357]), They include multiday and more convenient dosing, especially for the sustained release of short half-life drugs ([@b5-ppa-2-357]). The main drawback of this technology is that only a limited number of drugs can be delivered by passive diffusion from a patch, because low molecular weight, high lipophilic property, and a small required dose are essential for a molecule to permeate the skin ([@b5-ppa-2-357]). Thus the introduction of the first, unique patch for transdermal hormonal contraception (ethinyl estradiol/norelgestromin, EE/NGMN patch) was widely acknowledged as a significant step in the development of transdermal drug delivery ([@b42-ppa-2-357]).

The central aim of this article is to review the main evidence supporting the use of the transdermal contraceptive EE/NGMN patch, with particular reference to patient adherence and satisfaction.

Methods
=======

A Medline search was made during April 2008, to identify all types of articles in English on the EE/NGMN patch, including prospective open label and controlled clinical studies. The keywords were: "transdermal", "contraceptive", "ethinyl estradiol", "norelgestromin", "compliance", "adherence", "persistence", "acceptability", "therapeutic alliance", and "patient satisfaction". Congress communications on the same topics were also searched, to include more recent clinical studies. When no refererences are cited, the reader can assume that the author's clinical observations are presented.

Main characteristics and clinical development
=============================================

The EE/NGMN patch is an innovative, three-layer hormonal contraceptive system that provides similar efficacy to oral contraceptives, with the substantial benefit of once-weekly administration. The patch is applied once weekly for 3 consecutive weeks, followed by a patch-free week. As a result, users need only actively comply with dosing once weekly on the same day ([@b37-ppa-2-357]).

The transdermal contraceptive EE/NGMN patch has the same mechanisms of action as combined oral contraceptives. After the patch is applied, hormones appear rapidly in the circulation, reaching a plateau after approximately 48 hours, which is maintained at this level during the 7-day wear period. On average, each EE/NGMN patch delivers 150 μg of norelgestromin (the primary active metabolite of norgestimate) and 20 μg of ethinyl estradiol daily to the systemic circulation ([@b34-ppa-2-357]).

The pharmacokinetic properties ([@b1-ppa-2-357]; [@b5-ppa-2-357]) of the EE/NGMN transdermal patch provide particular benefits over combined oral contraceptives ([Table 1](#t1-ppa-2-357){ref-type="table"}).

Efficacy
========

Three pivotal phase III clinical studies have consistently confirmed the contraceptive efficacy of the transdermal EE/NGMN patch, either in comparison with oral contraceptives ([@b18-ppa-2-357]; [@b4-ppa-2-357]) or according to an open, non-comparative trial design ([@b54-ppa-2-357]).

Pooled analyses of pivotal trials on more than 3,300 women and more than 22,000 treatment cycles showed favorable results: the EE/NGMN patch had an overall annual probability of pregnancy (method failure plus user failure) of 0.8% and a method failure probability of 0.6%. Efficacy and cycle control were similar to those of established oral contraceptives, and were comparable across age and racial groups ([@b69-ppa-2-357]). Follicular size and incidence of ovulation proved to be significantly reduced among patch users compared with those in women using oral contraceptives, both in normal cycles and after planned dosing errors ([@b37-ppa-2-357]).

Besides controlled studies, effectiveness was tested in real life conditions. Results of a large European, open-label study evaluating women's experience with the transdermal contraceptive patch during routine use were recently disclosed at a congress ([@b19-ppa-2-357]; [@b20-ppa-2-357]). In the study, 573 healthy women were followed up for six, 4-week treatment cycles. The transdermal contraceptive patch was shown to be a reliable method of contraception, with a Pearl Index (the number of pregnancies per 100 women-years of use) of 0.43 (95% CI: −0.41 to 1.27) and a Pearl Index for patients who reported perfect compliance of 0.48 (95% CI: −0.47 to 1.43). Thus both indexes were comparable to those of other popular forms of hormonal contraception.

A further study ([@b56-ppa-2-357]) estimated the contraceptive effectiveness of the patch versus oral contraceptives in real life conditions. The probability of pregnancy with the transdermal patch was shown to be lower than with oral contraceptives in all age groups, included younger women ([Figure 1](#f1-ppa-2-357){ref-type="fig"}). Therefore, the effectiveness of the patch is expected to exceed that of oral contraceptives, due to an increased rate of perfect use.

Adhesion could be a potential concern, because optimal drug delivery can be achieved only if the patch remains adhered to the user's skin. In fact the adhesive reliability of the contraceptive patch has proved to be excellent and consistent: the two clinical trials showed that only 1.8% and 2.9% of patches required replacement because of complete or partial detachment, respectively. Furthermore, it was observed that patch adhesion tended to improve over treatment cycles, probably because participants learned the proper application technique with continued use. Finally, specific studies showed that the contraceptive patch detachment rate was unaffected by heat, humidity, and exercise ([@b68-ppa-2-357]).

In conclusion, the EE/NGMN patch provides, on a once-weekly schedule, at least the same efficacy as marketed oral contraceptives administered on a daily regimen, with the added benefits of sustained hormone concentrations and greater "forgiveness" of dosing errors. Even if a scheduled patch change is missed for 2 days during weeks 2 and 3 of a 4-week cycle, clinical efficacy is maintained, and backup contraception is not needed ([@b5-ppa-2-357]). Adhesion properties are reassuring for women who enjoy participating in exercise, as they can maintain all their usual activities including bathing, swimming, jogging, and using a whirlpool or a sauna ([@b1-ppa-2-357]; [@b68-ppa-2-357]).

Tolerability and safety
=======================

The pooled analysis of safety and tolerability data across three pivotal studies showed that the adverse effect profile of the EE/NGMN patch was fairly similar to that of oral contraceptives, the most frequent adverse events being headache and nausea ([Figure 2](#f2-ppa-2-357){ref-type="fig"}). A few notable differences were reported in patch users: transient, mild to moderate application site reactions, as expected, and breast discomfort symptoms, which generally resolved after 3 months of use. Local tolerability was shown to be good, with low potential for irritation and no potential for photo-toxicity ([@b53-ppa-2-357]). However, women with atopia and allergic skin diseases are more vulnerable to allergic reactions or local skin irritation.

Further studies addressed some safety issues and showed that oral and transdermal contraception with similar hormones induced similar effects on vascular risk markers ([@b26-ppa-2-357]; [@b28-ppa-2-357]). A review of post-marketing safety and surveillance data for progestin oral contraceptives containing norgestimate and ethinyl estradiol provided useful information about the relative rate of vascular events ([@b30-ppa-2-357]). These data fully supported the favorable cardiovascular safety profile of norgestimate-containing oral contraceptives. A recently published, nested, case-control, epidemiologic study, which compared different routes of administration, and included a further 17 months of follow up, showed that the risk of non-fatal venous thromboembolism was similar in the contraceptive patch and norgestimate-containing oral contraceptives with 35 μg of ethinyl estradiol ([@b23-ppa-2-357]; [@b25-ppa-2-357]). Furthermore, the EE/NGMN patch showed no evidence of an increased risk of cerebral venous sinus thrombosis compared with levonorgestrel-containing, norgestimate-containing, and desogestrel-containing oral contraceptives ([@b22-ppa-2-357]). Moreover, ischemic stroke and acute myocardial infarction were rarely reported among contraceptive patch users ([@b24-ppa-2-357]). Only one epidemiologic study reported a more than two-fold increase in the risk of venous thromboembolism, but not arterial thromboembolic events, for the transdermal contraceptive system, compared with the same risk in users of norgestimate-containing oral contraceptives ([@b7-ppa-2-357]). These data were not confirmed by other studies; moreover, the estimated incidence of venous thromboembolism per 100,000 women-years was 40.8 for contraceptive patch users, which is similar to that reported in studies of third generation progestins ([@b5-ppa-2-357]).

Therefore the EE/NGMN contraceptive patch experience confirms previously reported findings on safety in hormonal oral contraceptives: provided that they are not prescribed to women at risk, and that they contain a low dose of ethinyl estradiol and suitable progestins (eg, norgestimate), their net health benefit is great, even when the health risks are taken into account ([@b36-ppa-2-357]).

Perfect dosing
==============

Patch users were better able to follow the dosing regimen than users of daily oral contraceptive ([@b10-ppa-2-357]). Indeed transdermal contraception has been shown to improve the percentage of cycles with perfect dosing compared with oral contraceptives. Pooled data across the three pivotal studies showed that the percentage of cycles with perfect dosing was significantly higher with the patch than with oral contraceptives ([@b3-ppa-2-357]).

Age has often been reported as a factor affecting correct and consistent oral contraceptive use. Significantly, in the main comparative clinical trial conducted in North America, perfect use was consistent across age groups for the patch, while, as expected, rates of perfect use for oral contraceptives differed significantly by age ([@b2-ppa-2-357]). Adolescents (the age group most vulnerable to forgetting to take oral contraceptives and/or unintentional mistakes and thus inadequate adherence) had the greatest increase in compliance with transdermal contraception over oral contraceptives (87.7% vs 67.7%) ([@b4-ppa-2-357]). This significant advantage should be considered especially when counseling adolescents on contraceptive choices.

As a consequence of improved compliance, a base-case analysis showed that increased perfect use of the patch would result in a saving of US\$249 per woman over 2 years compared with oral contraceptives ([@b56-ppa-2-357]).

Transdermal contraception has further benefits, encouraging perfect use, in addition to its effectiveness in preventing unwanted pregnancies and its favorable safety profile. Most women consider the patch a convenient and simple method: in a recent study, more than 70% preferred or strongly preferred this contraceptive method compared with previous forms of contraception ([@b20-ppa-2-357], [Table 2](#t2-ppa-2-357){ref-type="table"}). Convenience and simplicity of use were predominant factors in this high level of preference and contributed to the good acceptability of the patch.

Patient adherence and acceptability
===================================

When considering patient choices among contraceptive methods, the reasons for treatment compliance and adherence need to be carefully considered. As originally defined by Sackett in his 1976 landmark publication ([@b50-ppa-2-357]), the term compliance refers to the extent to which the behavior of the patient coincides with the doctor's order. The term compliance has long been criticized as denoting obedience by passive patients to doctors as authoritity figures, in the traditional hierarchical doctor/patient relationship. Therefore, a more consistent definition encompassing consensus was sought.

Adherence can also refer to a therapeutic plan, mutually agreed between patient and doctor, in which the patient expects to understand the information provided, and to cooperate by adding their personal perception and experience ([@b41-ppa-2-357]). Because they actively "adhere" to therapeutic decisions, patients are involved in mutual decision making with their doctor, reaching a "therapeutic alliance", a valuable predictor of favorable outcome.

However, adherence needs to be combined with persistence for the duration of treatment, to optimize efficacy and satisfaction with use. In this way, personal reward, can encourage repetition of the same behavior.

The major difference detected in the oral contraceptive failure rate with perfect use (0.1%), and the failure rate in real life (6.9% after 12 months) probably reflects at least some degree of dissatisfaction with available methods ([@b58-ppa-2-357]). Every physician prescribing a contraceptive should carefully evaluate patient satisfaction, and factors that could potentially enhance it. This satisfaction is closely related to the success of treatment, just as a favorable patient/physician relationship influences treatment adherence. Oral contraceptive non-adherence can be explained in several ways, that is, early discontinuation (drop-outs), sporadic non-adherence due to forgetfulness and/or unintentional mistakes (inconsistent use), and systematic non-adherence over time ([Table 3](#t3-ppa-2-357){ref-type="table"}).

Early discontinuation is the most critical issue, as women who discontinue oral contraceptives often choose a less reliable contraceptive or no method at all, thus experiencing more unintended pregnancies. A significant predictor of early discontinuation is the occurrence of adverse events, with an increased risk of discontinuation as the number of adverse effects increases ([@b47-ppa-2-357]). Weight gain is the most commonly reported adverse event leading to drop out. It seems to be a subjective complaint, however, as no evidence of a causal association between hormonal contraception and weight gain was found by the Cochrane group in their recent systematic review ([@b14-ppa-2-357]).

Key predictors for inconsistent use are lack of an established routine for pill-taking and failure to understand instructions, thus emphasizing that quality of information provided by the physician and mutual decision making are influential in achieving long-term adherence.

As shown by measuring compliance using electronic devices, women tend to become less careful about their pill-taking behavior over time ([@b40-ppa-2-357]). This change may reflect personalized schedules of use, learning to make up for occasional missed pills, or a kind of fatigue during continuous use. In addition, the same study showed that women tend to under-report their missed pills: the proportion of women missing at least three pills in a cycle according to the electronic data was triple that derived from the women's diaries (30%--51% vs 10%--14%). Missing pills were more likely to be clustered at the weekends and on consecutive days ([@b40-ppa-2-357]), with a consequent increased risk of irregular bleeding and unintended pregnancies.

An analysis of women's self described reasons for missing pills showed that the three most reported reasons were being away from home, simply forgetting to take a pill, and not having the pill pack with them/being unable to obtain a new pack of pills in time for the beginning of the new cycle ([@b55-ppa-2-357]). Further predictors for inconsistent use are reported in [Table 4](#t4-ppa-2-357){ref-type="table"}.

To date, systematic "reasoned" non-adherence, whereby patients decide to change the dosage and/or dosing interval without informing the doctor, does not seem to have been adequately investigated. This kind of non-adherence can be avoided to some extent, by jointly establishing the ultimate objective, which differs according to the age of the woman. Evaluating a woman's particular needs or specific fears (including fear of forgetting to taking the pill, or fear of a negative effect on the body) and other such emotions including general anxiety which could foster inconsistent usage ([@b60-ppa-2-357]) can help in doctor/patient decision making. In a recent cross-sectional multicenter study, designed to assess the reasons for selecting the contraceptive pill, the skin patch, or the vaginal ring in 9700 women, the main reasons for choosing one type of hormonal treatment over another, consistent with the findings of previous studies, were convenience and frequency of use associated with lower probability of inadvertent omission ([@b29-ppa-2-357]). In addition, including the husband in family planning programs has been shown to increase the use of modern contraception ([@b57-ppa-2-357]).

Adherence to treatment has been shown to be statistically superior for the transdermal patch compared with that observed with oral contraceptives ([Figure 3](#f3-ppa-2-357){ref-type="fig"}), in all age groups ([@b3-ppa-2-357]) and in all treatment cycles ([@b11-ppa-2-357]). The same is true for user satisfaction: in a study presented at a recent conference ([@b20-ppa-2-357]), the mean satisfaction score was shown to increase when women switched from previous contraceptive methods to the transdermal patch ([Table 2](#t2-ppa-2-357){ref-type="table"}).

Furthermore, in a recently published Cochrane review comparing contraceptive effectiveness and compliance in non-oral methods versus oral contraceptives, the authors concluded that although effectiveness was similar, the contraceptive patch group reported better compliance than the oral contraceptive group (odds ratio = 2.05 and 2.76 in two trials). In one crossover ring trial greater non-compliance was reported by ring users ([@b32-ppa-2-357]).

Benefits of hormonal contraception: tailoring treatment
=======================================================

Today women are still largely unaware of the non-contraceptive health benefits associated with hormonal contraceptives ([Table 5](#t5-ppa-2-357){ref-type="table"}). Choosing a contraceptive method is a mutual decision that should take into account, besides the risks, the expected non-contraceptive benefits. A doctor should evaluate these with the woman in order to agree on a tailored program to achieve her adherence and persistence of use.

Adolescents
===========

The most popular form of birth control among adolescents is oral contraceptives ([@b49-ppa-2-357]). However, adolescents tend to miss oral contraceptive pills, with a rate of failure close to 5% to 18%, that is, approximately 55% higher than that found in adult users, leading to a greater risk of unintended pregnancies ([@b49-ppa-2-357]; [@b17-ppa-2-357]). In addition, less than 60% of adolescents report perfect compliance with oral contraceptives, the rate of discontinuation within 1 year being approximately 64% ([@b49-ppa-2-357]).

A number of specific studies have examined adolescent use of the transdermal EE/NGMN contraceptive patch, confirming that it can provide a convenient form of reversible contraception ([@b31-ppa-2-357]). Its ease of use and the fact that it does not require daily attention are well acknowledged by adolescents who have used it ([@b49-ppa-2-357]).

The finding that users of the transdermal EE/NGMN contraceptive patch generally experience minimal changes in body weight could be relevant to adolescent use, because weight gain is a significant predictor of early discontinuation of combined hormonal contraceptives in this age subgroup population ([@b17-ppa-2-357]).

Improvement of facial acne, relief of dysmenorrheal symptoms, and reduction of heavy periods are further benefits. In a recent study of Thai adolescent women, participants reported a decrease in dysmenorrhea, shorter duration of bleeding, and an improvement of facial acne ([@b38-ppa-2-357]). These data confirm the previously reported findings of Harel's study, that is, an improvement in the facial acne of one third of adolescents, and favorable results in a preliminary study of patch use among women suffering from papulo-pustular inflammatory acne. Clinical improvement started from the fourth month, with lesions almost disappearing in some patients ([@b6-ppa-2-357]). Furthermore, in women with acne vulgaris, an oral contraceptive containing norgestimate has been shown to be effective in normalizing skin-surface lipids in seborrheic areas, while skin hydration did not undergo any important changes ([@b51-ppa-2-357]).

These therapeutic effects have been ascribed to the progestin component of the patch, which interacts selectively with the progesterone receptor and, therefore, does not stimulate androgen receptors ([@b65-ppa-2-357]). Norgestimate, which is metabolized to norelgestromin, has negligible binding affinities for the androgen receptor and for the sex hormone-binding globulin (SHBG), reflecting the low androgenicity of this progestin, which is a desirable property particularly when signs of skin hyperandrogenism such as acne appear. In addition, the antiandrogenic activity of norgestimate and of norelgestromin has recently been demonstrated, using a human androgen-dependent stable-transfected cell line ([@b35-ppa-2-357]). Finally, in skin tissue, norgestimate is a potent inhibitor of 5α-reductase, the enzyme responsible for transforming testosterone in the more potent 5α-dihydrotestosterone ([@b43-ppa-2-357]). Given these findings, the contraceptive EE/NGMN patch could be useful in women with disorders of androgen excess ([@b65-ppa-2-357]).

Adult women
===========

Some evidence indicates that the patch is particularly beneficial for emotional and physical well-being, and for premenstrual syndrome, which is more common in women over the age of 30 ([@b62-ppa-2-357]).

Women who use the transdermal contraceptive patch have been reported to give higher ratings than oral contraceptive users when questioned on their emotional and physical well-being, and on improvements in premenstrual symptoms. In a randomized study comparing the patch with an oral contraceptive containing desogestrel and ethinyl estradiol, emotional and physical well-being were significantly higher with the patch than with the oral contraceptive, the difference being clustered in women aged 34 years and over. The same difference in improvement of premenstrual symptoms (p \< 0.01) favoring the contraceptive patch was found, once again especially in women aged 34 years and over ([@b59-ppa-2-357]).

These non-contraceptive beneficial effects may, at least in part, explain the high level of satisfaction reported by users of the transdermal patch and may contribute to their adherence to treatment.

The perimenopause
=================

The perimenopause is a period lasting up to 5 to 6 years during which women experience menstrual cycle changes and may also experience typical menopausal signs and symptoms, such as bone mineral density loss, vasomotor instability, and joint pain. Some women erroneously believe that they no longer need contraception, although statistics show that up to 80% of women aged 40 to 44 years can conceive ([@b52-ppa-2-357]). For these women, hormonal contraception, which offers protection against undesired pregnancy as well as correction of hormonal imbalance, is more suitable than hormone replacement therapy, which offers only the latter ([@b27-ppa-2-357]).

In hormonal combinations, contraceptives containing norgestimate have demonstrated prominent changes in bone resorption and formation markers in patients with hypothalamic amenorrhea, a young population experiencing significant bone loss ([@b15-ppa-2-357]). These findings suggest that suitable hormonal combinations can decrease the rate of bone turnover and attenuate bone loss in at risk populations, such as perimenopausal women (appropriate calcium and vitamin D daily intake must be checked and integrated if necessary).

In conclusion, in a mutual decision making process with their physician, healthy perimenopausal women can be assured that the transdermal patch is a useful and reliable contraceptive method, and an alternative to oral formulations, which can improve perimenopausal symptoms, reduce some long-term health risks, and enhance quality of life ([@b27-ppa-2-357]).

Satisfaction with the transdermal patch
=======================================

Because human behavior tends to be repeated when rewarded, satisfaction with a contraceptive method is essential for long-term adherence, and depends mainly on selecting the optimal contraceptive for the couple ([Table 3](#t3-ppa-2-357){ref-type="table"}).

A large European study compared patient attitudes (satisfaction and preference) toward the transdermal contraceptive patch and toward previous contraceptive methods. Of all the women surveyed, 88% said that they were satisfied or very satisfied with the patch and 70.1% preferred the patch to their previous method of contraception, which in 72.4% had been an oral contraceptive. The main reasons for this preference were: convenience (40.9%), ease of use/simplicity (31.5%), and fewer side effects (19.3%) ([@b20-ppa-2-357]).

In another similar study 74.9% of women preferred the patch, mainly because of its convenience (50.2%) and simplicity (32.5%); 91% were satisfied or very satisfied with the patch ([@b63-ppa-2-357]).

Another clinical study showed that patch users were significantly more satisfied with their contraceptive than users of oral contraceptives (p = 0.001), and that satisfaction was associated with duration of use and mental well-being ([@b61-ppa-2-357]).

Patch users sometimes refer to inconveniences, which can depend either on the transdermal route of administration or on the hormonal mode of action. These include application site reactions or pruritus, mainly in subjects with irritated or sensitive skin (but \<2% of participants discontinued treatment for this reason), incomplete adhesive reliability (although only a minimal proportion of patches requires replacement), patch visibility (which is a problem for only a limited subset of subjects; applying the patch to the buttock or to lower abdomen guarantees discretion), appearance of a dark ring around the patch (probably due to adhesive components; washing the area normally where the patch is attached could resolve this inconvenience), unpredictable vaginal bleeding (an adverse event, common even with oral contraceptives, which generally decreased over time) ([@b4-ppa-2-357]; [@b53-ppa-2-357]). Therefore, a further optimization of structural support and hormones of the patch could help improve esthetics and cutaneous tolerability, and reduce breakthrough bleeding or spotting.

Conclusions
===========

The transdermal EE/NGMN contraceptive patch is an excellent choice for women of any age who desire convenient, easy-to-use, reversible, hormonal contraception. The contraceptive efficacy of the patch is comparable with that of oral contraceptives while adherence and persistence of use are consistently better for the patch in all age groups. The patch enables a contraceptive to be tailored to suit the needs of women of all ages and characteristics. Combined with a valuable doctor-patient relationship which permits the development of a therapeutic alliance, the patch has received higher satisfaction ratings in addition to ensuring effectiveness and safety.
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###### 

Clinical advantages of a transdermal system for contraception

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Allows longer, multiday, more convenient dosing intervals than the once daily administration of oral contraceptives ([@b5-ppa-2-357])
  Improves patient compliance ([@b1-ppa-2-357])
  Can reduce side effects by avoiding peak high concentrations and ensuring continuous, sustained hormonal release ([@b1-ppa-2-357])
  Avoids first-pass liver metabolism, thus enabling the use of lower doses to achieve efficacy and reducing the chances of drug interactions ([@b1-ppa-2-357])
  Unaffected by bouts of vomiting and/or diarrhea, which prevent adequate absorption by the gut ([@b1-ppa-2-357])
  Can easily be withdrawn if necessary ([@b5-ppa-2-357])
  More forgiving of dosing errors: back up contraception not needed if patch change is forgotten for 1--2 days in the middle of a 4-week cycle (weeks 2 and 3) ([@b1-ppa-2-357])
  Eases compliance of use in cases of jet-lag and frequent flying
  Allows safe administration in women with lactose and gluten intolerance
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Satisfaction, compliance and preference for the patch

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------
  573 women aged 18--46 years were enrolled to use the patch for six 4-week treatment cycles. In total, 467 women (81.5%) completed the study. Most women (410, 71.5%) had been using a contraceptive method before the start of the study ([@b20-ppa-2-357]).   
  **At baseline**                                                                                                                                                                                                                                                
  Satisfaction with their previous method of contraception                                                                                                                                                                                                       56.2%
  Oral contraceptive users reported missing doses (some, most, or all of the time)                                                                                                                                                                               38.7%
  **After using transdermal contraception (6 cycles)**                                                                                                                                                                                                           
  Satisfaction                                                                                                                                                                                                                                                   
   Satisfied or very satisfied with the patch                                                                                                                                                                                                                    88%
   Find the patch convenient or very convenient                                                                                                                                                                                                                  90%
  Compliance                                                                                                                                                                                                                                                     
   Cycles with perfect compliance                                                                                                                                                                                                                                89.5%
  Preference or strong preference for the patch                                                                                                                                                                                                                  
   Shift from oral contraception                                                                                                                                                                                                                                 67.5%
   Shift from barrier contraception                                                                                                                                                                                                                              84.8%
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------

###### 

Main determinants of compliance, adherence, and persistence

  Compliance                                                 Adherence                                Persistence                                                                                                                                    
  ---------------------------------------------------------- ---------------------------------------- ----------------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Quality of doctor/patient relationship (Probsfield 1991)   Inconvenient usage ([@b66-ppa-2-357])    No established routine for intake ([@b48-ppa-2-357])                          Poor quality of doctor/patient relationship ([@b44-ppa-2-357])   Mutual decision making that leads to rewards in the form of personal need satisfaction ([@b9-ppa-2-357])
  Active involvement of woman (Probsfield 1991)              Undesirable effects ([@b66-ppa-2-357])   Did not read or understand package leaflet ([@b48-ppa-2-357])                 Couple conflicts ([@b33-ppa-2-357])                              
  Active involvement of partner (Probsfield 1991)                                                     Inadequate instructions by doctor ([@b48-ppa-2-357])                                                                                           
                                                                                                      Inconvenient usage ([@b48-ppa-2-357])                                                                                                          
                                                                                                      Undesirable effects ([@b48-ppa-2-357])                                                                                                         
                                                                                                      Negative partner attitude towards hormonal contraception ([@b57-ppa-2-357])                                                                    

###### 

Key predictors for inconsistent contraceptive use

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Country of residence:** significant differences among countries may reflect cultural differences, problem/free access to contraception, or different counseling attitudes
  **Low income:** higher risk of contraceptive failure and lower likelihood of resuming contraceptive use, possibly due to education problems
  **Age:** very young women are more likely to be inconsistent users than older women ([@b39-ppa-2-357])
  **Problems with access:** difficulties in obtaining the contraceptive ([@b64-ppa-2-357])
  **Insufficient involvement of the partner** ([@b57-ppa-2-357])
  **Lack of contraceptive knowledge or negative experience with the contraceptive method** (both associated with more requests for abortion) ([@b45-ppa-2-357])
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Well-established non-contraceptive benefits of hormonal methods

  Benefit                                                    Mechanism
  ---------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  Relief of dysmenorrhea                                     Reduction of prostaglandin levels in menstrual fluid ([@b13-ppa-2-357]); reduction of heavy periods; symptomatic treatment of endometriosis
  Prevention of ovulation pain                               Inhibition of ovulation ([@b21-ppa-2-357])
  Contribution to the resolution of iron-deficiency anemia   Reduction of blood loss and heavy periods ([@b36-ppa-2-357])
  Treatment of polycystic ovary syndrome                     Inhibition of ovarian activity; reduction of androgen excess; regulation of menstrual cycles ([@b67-ppa-2-357])
  Treatment of endometriosis                                 Down regulation of the hypothalamus-pituitary-ovarian pathway ([@b46-ppa-2-357]); reduced stimulation of endometrial ectopic tissue
  Reduction of the risk of endometrial cancer                Progestin-mediated suppression of estrogen-induced proliferation of endometrial cells ([@b36-ppa-2-357]; [@b16-ppa-2-357])
  Reduction of the risk of ovarian cancer                    Suppression of ovulation (suggested) ([@b36-ppa-2-357]; [@b16-ppa-2-357]; [@b8-ppa-2-357])
